Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe-Reference-Cited by-同舟云学术

Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

Published:2022-01 Issue:1 Volume:9 Page:46-58
ISSN:2215-0366
Container-title:The Lancet Psychiatry
language:en
Short-container-title:The Lancet Psychiatry

Author:

Bugarski-Kirola Dragana,Arango Celso,Fava Maurizio,Nasrallah Henry,Liu I-Yuan,Abbs Brandon,Stankovic Srdjan

Funder

ACADIA Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference36 articles.

1. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study;Bobes;J Clin Psychiatry,2010

2. Negative symptoms of schizophrenia: new developments and unanswered research questions;Galderisi;Lancet Psychiatry,2018

3. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers;Artaloytia;Am J Psychiatry,2006

4. Clinical pharmacology of atypical antipsychotics: an update;Mauri;EXCLI J,2014

5. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms;Arango;Eur Psychiatry,2004

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Innovative Pharmacological Targets in Schizophrenia;Current Treatment Options in Psychiatry;2024-07-13

2. Antipsychotic-Induced QT Prolongation and Torsade de Pointes in Patients with Mental Disorders: A Review;Safety and Risk of Pharmacotherapy;2024-05-16

3. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments;Pharmacopsychiatry;2024-05-06

4. New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction;Biological Psychiatry;2024-05

5. Beyond dopamine: Novel strategies for schizophrenia treatment;Medicinal Research Reviews;2024-04-23